等待开盘 11-16 09:30:00 美东时间
-0.175
-4.79%
11月14日,IMMP(IMMP)收跌4.79%,报3.48美元,成交额5.24万美元,市值2564.25万美元。 行情数据 • 开盘价:3.65美元 • 最高...
11-14 08:40
Immutep Limited (NASDAQ:IMMP) on Tuesday announced that investigators in its Phase 2 trial observed promising preliminary long-term outcomes for its lead candidate, alongside securing a new U.S. patent that shields its combination therapies through 2038. Clinical investigators evaluated eftilagimod ...
11-12 00:27
11月7日,IMMP(IMMP)收涨24.16%,报3.34美元,成交额30.71万美元,市值2461.17万美元。 行情数据 • 开盘价:2.69美元 • 最...
11-07 08:38
Immutep Limited announced that data from two clinical trials of its MHC Class II agonist, eftilagimod alfa (efti), will be presented at two international congresses in November and December 2026. At the CTOS 2026 Annual Meeting in Seoul, survival data from the EFTISARC-NEO Phase II trial evaluating efti in combination with KEYTRUDA and radiotherapy for resectable soft tissue sarcoma will be presented. At the ESMO Immuno-Oncology & Advanced Therap...
11-05 13:00
11月4日,IMMP(IMMP)收跌2.44%,报3美元,成交额3.69万美元,市值2204.2万美元。 行情数据 • 开盘价:3.03美元 • 最高价:3....
11-04 08:43
Immutep focuses on advancing efti for HNSCC (CPS <1) and neoadjuvant STS, with trials targeting H2 CY27. IMP761, an anti-LAG-3 antibody for autoimmune diseases, is now a co-priority and will be featured at ACR 2026. The root cause analysis of TACTI-004 identified structural differences in efti manufacturing scales, leading to a new 200 L scale production. The company received A$0.86 million from Australia’s R&D Tax Incentive and €1.36 million fro...
10-29 12:00
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Im...
10-28 20:02
Immutep Limited received a €1.36 million cash payment from the French Government under its CIR research tax incentive program for eligible R&D activities in 2025. This follows an A$0.86 million rebate from Australia and eligibility for Germany’s R&D tax incentive. The non-dilutive funding will support R&D for eftilagimod alfa (efti) and IMP761. Immutep’s cash reach extends into the first half of 2028.
10-28 12:00
10月28日,IMMP(IMMP)收涨1.61%,报3.15美元,成交额4.26万美元,市值2321.06万美元。 行情数据 • 开盘价:3.1美元 • 最高价...
10-28 07:44
Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep Limited has filed...
10-26 05:55